Aldeyra Therapeutics (ALDX) Income from Continuing Operations (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Income from Continuing Operations came in at 3452619.0 in Q1 2026, up 80.38% YoY from 1914044.2 in Q1 2025, and up 47.88% on a QoQ basis from 6624308.0 in Q4 2025.
Aldeyra Therapeutics (ALDX) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Income from Continuing Operations data on file, last reported at 3452619.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 80.38% year-over-year to 3452619.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34590045.0 (up 52.23% YoY) and the FY2025 annual result came in at 38548602.0, up 34.45% from the prior year.
- Income from Continuing Operations advanced to 3452619.0 in Q1 2026, from 6624308.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 3452619.0 in Q1 2026 to a low of 41499272.0 in Q1 2023.
- A 5-year average of 15990436.35 and a median of 15934978.0 in 2024 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 80.52% in 2024, down 263.5% in 2024.
- Tracing ALDX's Income from Continuing Operations over 5 years: stood at 13153608.0 in 2022, then surged by 66.67% to 4383715.0 in 2023, then slumped by 263.5% to 15934978.0 in 2024, then soared by 58.43% to 6624308.0 in 2025, then jumped by 47.88% to 3452619.0 in 2026.
- The last three Income from Continuing Operations figures came in at 3452619.0 (Q1 2026), 6624308.0 (Q4 2025), and 14024588.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Aldeyra Therapeutics | 90.18 Mn | 90.18 Mn | - | -5.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.43 Mn |
| Mar 31, 2026 | -3.45 Mn |
| Dec 31, 2025 | -6.62 Mn |
| Sep 30, 2025 | -14.02 Mn |
| Jun 30, 2025 | -10.49 Mn |
| Mar 31, 2025 | -17.60 Mn |
| Dec 31, 2024 | -15.93 Mn |
| Sep 30, 2024 | -22.02 Mn |
| Jun 30, 2024 | -16.85 Mn |
| Mar 31, 2024 | -8.08 Mn |
| Dec 31, 2023 | -4.38 Mn |
| Sep 30, 2023 | -15.18 Mn |
| Jun 30, 2023 | -25.96 Mn |
| Mar 31, 2023 | -41.50 Mn |
| Dec 31, 2022 | -13.15 Mn |
| Sep 30, 2022 | -19.03 Mn |
| Jun 30, 2022 | -18.97 Mn |
| Mar 31, 2022 | -18.58 Mn |
| Dec 31, 2021 | -15.35 Mn |
| Sep 30, 2021 | -27.38 Mn |